Literature DB >> 1671889

Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy.

E Arnaudo1, M Dalakas, S Shanske, C T Moraes, S DiMauro, E A Schon.   

Abstract

Long-term zidovudine therapy in patients with human immunodeficiency virus (HIV) infection can cause a destructive mitochondrial myopathy with histological features of ragged-red fibres (RRF) and proliferation of abnormal mitochondria. In 9 zidovudine-treated patients with this myopathy we found severely reduced amounts (up to 78% reduction vs normal adult controls) of mitochondrial DNA (mtDNA) in muscle biopsy specimens by means of Southern blotting. In 2 HIV-positive patients who had not received zidovudine, muscle mtDNA content did not differ from that in the 4 controls. Depletion of mtDNA seems to be reversible, since 1 patient showed a substantial reduction in RRF and a concomitant pronounced increase in muscle mtDNA content after zidovudine therapy was discontinued. Depletion of muscle mtDNA is probably due to zidovudine-induced inhibition of mtDNA replication by DNA polymerase gamma and is not a secondary effect of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671889     DOI: 10.1016/0140-6736(91)91294-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  95 in total

1.  Hyperlactataemia and hepatic steatosis: mitochondrial toxicity of nucleoside reverse transcriptase inhibitors.

Authors:  D Pao; C Watson; B Peters; S B Lucas; R F Miller
Journal:  Sex Transm Infect       Date:  2001-10       Impact factor: 3.519

Review 2.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity.

Authors:  Edward E McKee; Alice T Bentley; Matthew Hatch; Joel Gingerich; Delia Susan-Resiga
Journal:  Cardiovasc Toxicol       Date:  2004       Impact factor: 3.231

Review 4.  Mitochondrial injury. Lessons from the fialuridine trial.

Authors:  P Honkoop; H R Scholte; R A de Man; S W Schalm
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 5.  Structural insight on processivity, human disease and antiviral drug toxicity.

Authors:  Y Whitney Yin
Journal:  Curr Opin Struct Biol       Date:  2010-12-24       Impact factor: 6.809

Review 6.  Progressive external ophthalmoplegia characterized by multiple deletions of mitochondrial DNA: unraveling the pathogenesis of human mitochondrial DNA instability and the initiation of a genetic classification.

Authors:  Gert Van Goethem; Jean-Jacques Martin; Christine Van Broeckhoven
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 7.  The mitochondrial DNA polymerase in health and disease.

Authors:  William C Copeland
Journal:  Subcell Biochem       Date:  2010

8.  Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy.

Authors:  T M Sinnwell; K Sivakumar; S Soueidan; C Jay; J A Frank; A C McLaughlin; M C Dalakas
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 9.  Neuromuscular diseases associated with HIV-1 infection.

Authors:  Jessica Robinson-Papp; David M Simpson
Journal:  Muscle Nerve       Date:  2009-12       Impact factor: 3.217

Review 10.  A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial disease.

Authors:  Christopher M Bailey; Karen S Anderson
Journal:  Biochim Biophys Acta       Date:  2010-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.